SEATTLE — GSP301, a nasal spray containing a fixed-dose combination of olopatadine hydrochloride/mometasone furoate, is a safe and effective treatment for reducing ...

November 29, 2010 (Phoenix, Arizona) — Once-daily mometasone furoate nasal spray relieves nighttime and early morning nasal congestion in patients with seasonal allergic rhinitis, according to a post ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ryaltris combines olopatadine hydrochloride and ...

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an ...

Schering-Plough reported that the FDA has approved a new scent-free formulation of Nasonex prescription nasal inhaled steroid. Nasonex remains the first and only once-daily prescription nasal inhaled ...

This article is part of The Clinical Advisor’s conference coverage from the American Academy of Allergy, Asthma & Immunology in Orlando, Florida. Our staff will report on medical research related to ...

The EVEREST trial directly compared biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...

Acute rhinosinusitis is a common disease with an increasing incidence rate. It causes substantial costs to the individual and to society through healthcare consumption and absence from work. The use ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...